Category Archives: Science Research Technology

Science Research Technology

Asahi Kasei“s Microza™ hollow-fiber membrane selected for desalination plant in Kuwait

The company“s largest order for water filtration membranes

Dusseldorf, October 30, 2017 – Microza™ Dusseldorf, October 30, 2017 – Microza™ hollow-fiber membrane for water treatment from Asahi Kasei was selected as pretreatment membrane for the Doha Phase 1 reverse osmosis (RO) seawater desalination plant to be built near Kuwait City by Doosan Heavy Industries and Construction, a major Korean plant construction company. Reverse Osmosis is a method of producing fresh water by removing salt ions from seawater with a special membrane at high pressure.

The Asahi Kasei membrane treatment capacity for this project is scheduled to be 610,000 tons per day, representing the largest hollow-fiber filtration membrane order received by Asahi Kasei.

Many RO plants for seawater desalination are planned in Kuwait and other countries of the Middle East to address chronic shortages of fresh water, with microfiltration (MF) and ultrafiltration (UF) membranes including Asahi Kasei“s Microza™ being adopted as pre-treatment membrane.

In addition to being widely used around the world in the fields of potable water production, wastewater treatment, and water recycling, Microza™ has a growing track record as pre-treatment membrane for RO in the Middle East. Microza™ was selected for the Doha Phase 1 Plant in recognition of its outstanding performance and reliable operation, and Asahi Kasei will actively continue to focus on meeting growing demand in the Middle East.

Outline of the Doha Phase 1 Plant

LocationDoha, Kuwait City, Kuwait
Capacity610,000 tons/day (Asahi Kasei membrane)
ConcessionaireKuwait Ministry of Electricity and Water
ContractorDoosan Heavy Industries and Construction Co., Ltd.

About Microza™
Based on Asahi Kasei“s original membrane-formation technology, Microza™ hollow-fiber membrane made of polyvinylidene fluoride (PVDF) exhibits outstanding physical strength and chemical resistance, with high filtration performance as well as long-term durability in water treatment applications exceeding competing PVDF membranes. Asahi Kasei is one of the world“s leading suppliers of hollow-fiber membrane and systems for water treatment, with its Microza™ membrane used at over 1,600 plants worldwide. In the United States market for membrane-process potable water clarification systems, the world“s largest, Microza™ holds the leading share. Adoption of Microza™ has also been growing firmly in many countries which face water shortages and growing needs for improved water quality, including China, Korea, Singapore, Thailand, Indonesia, and Middle Eastern countries. Asahi Kasei will continue to contribute to solutions for a wide range of environmental problems related to water resources throughout the world.

About Asahi Kasei
The Asahi Kasei Corporation is a globally active technology company with operations in the Material, Homes, and Health Care business. The Material division encompasses fibers & textiles, petrochemicals, performance polymers, performance materials, consumables, battery separators, and electronic devices. The Homes division provides housing and construction materials to the Japanese market. The Health Care division includes pharmaceuticals, medical devices, and acute critical care devices and systems. With approximately 34,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world with sustainable products and technologies.

For more information, please contact:

http://www.asahi-kasei.co.jp/asahi/en/

https://www.asahi-kasei.eu/

Company contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-Mail: Sebastian.Schmidt@asahi-kasei.eu

Press contact
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Telefon: +49 (0) 6172 27159 12
Phone: +49 (0) 175 903 42 29
E-Mail: h.kuell@financial-relations.de

for water treatment from Asahi Kasei was selected as pretreatment membrane for the Doha Phase 1 reverse osmosis (RO) seawater desalination plant to be built near Kuwait City by Doosan Heavy Industries and Construction, a major Korean plant construction company. Reverse Osmosis is a method of producing fresh water by removing salt ions from seawater with a special membrane at high pressure.

The Asahi Kasei membrane treatment capacity for this project is scheduled to be 610,000 tons per day, representing the largest hollow-fiber filtration membrane order received by Asahi Kasei.

Many RO plants for seawater desalination are planned in Kuwait and other countries of the Middle East to address chronic shortages of fresh water, with microfiltration (MF) and ultrafiltration (UF) membranes including Asahi Kasei“s Microza™ being adopted as pre-treatment membrane.

In addition to being widely used around the world in the fields of potable water production, wastewater treatment, and water recycling, Microza™ has a growing track record as pre-treatment membrane for RO in the Middle East. Microza™ was selected for the Doha Phase 1 Plant in recognition of its outstanding performance and reliable operation, and Asahi Kasei will actively continue to focus on meeting growing demand in the Middle East.

Outline of the Doha Phase 1 Plant

Location
Doha, Kuwait City, Kuwait
Capacity
610,000 tons/day (Asahi Kasei membrane)
Concessionaire
Kuwait Ministry of Electricity and Water
Contractor
Doosan Heavy Industries and Construction Co., Ltd.

About Microza™
Based on Asahi Kasei“s original membrane-formation technology, Microza™ hollow-fiber membrane made of polyvinylidene fluoride (PVDF) exhibits outstanding physical strength and chemical resistance, with high filtration performance as well as long-term durability in water treatment applications exceeding competing PVDF membranes. Asahi Kasei is one of the world“s leading suppliers of hollow-fiber membrane and systems for water treatment, with its Microza™ membrane used at over 1,600 plants worldwide. In the United States market for membrane-process potable water clarification systems, the world“s largest, Microza™ holds the leading share. Adoption of Microza™ has also been growing firmly in many countries which face water shortages and growing needs for improved water quality, including China, Korea, Singapore, Thailand, Indonesia, and Middle Eastern countries. Asahi Kasei will continue to contribute to solutions for a wide range of environmental problems related to water resources throughout the world.

About Asahi Kasei
The Asahi Kasei Corporation is a globally active technology company with operations in the Material, Homes, and Health Care business. The Material division encompasses fibers & textiles, petrochemicals, performance polymers, performance materials, consumables, battery separators, and electronic devices. The Homes division provides housing and construction materials to the Japanese market. The Health Care division includes pharmaceuticals, medical devices, and acute critical care devices and systems. With approximately 34,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world with sustainable products and technologies.

For more information, please contact:

http://www.asahi-kasei.co.jp/asahi/en/

https://www.asahi-kasei.eu/

Company contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-Mail: Sebastian.Schmidt@asahi-kasei.eu

Press contact
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Telefon: +49 (0) 6172 27159 12
Phone: +49 (0) 175 903 42 29
E-Mail: h.kuell@financial-relations.de

The Asahi Kasei Group is a diversified group of companies led by Asahi Kasei Corp., with operations in the Material, Homes, and Health Care business sectors. Asahi Kasei distributes its innovative technologies and unique materials on markets worldwide.
With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world.

Company-Contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-Mail: Sebastian.Schmidt@asahi-kasei.eu
Url: https://www.asahi-kasei.eu/

Press
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Phone: +49 (0) 6172 27159 12
E-Mail: h.kuell@financial-relations.de
Url: http://www.financial-relations.de

Science Research Technology

CeramOptec adds splicing applications to its portfolio

High precision fusion splicing of end caps and optical fibers

CeramOptec adds splicing applications to its portfolio

Fiber cables with ferrules (Source: @ CeramOptec GmbH)

Bonn, October 11, 2017 – CeramOptec, the specialist for multimode optical fibers, manufactured from quartz glass, has added splicing applications to its product portfolio. Based on the utilization of the CO2-Laser-Systems Nyfors SmartsplicerTM, in whose development CeramOptec participated directly, the biolitec subsidiary from Bonn is, as of now, able perform high precision, individually customized fusion splicing of end caps and various optical fibers. The software controlled splicing system is built based on the patented Axicon SplicingTM beam formation technology and projects a ring-shaped laser focal point, whose diameter can be adjusted according to the respective application. The energy from the laser is distributed evenly and projected precisely on the intended splicing area. This way, especially end caps with larger radii can be fused to a fiber through the laser much more precise and efficient than by means of conventional splicing devices. The system is also particularly well suited for the splicing of photonic crystal and gradient index fibers. Applications like the active collapsing of fibers, as well as rounding off and tapering of fiber ends can be achieved with the new splicing laser with previously unobtainable precision. The very stable software control and high precision of all optical and mechanical components guarantee the exact reproducibility of production results, even in highly demanding manufacturing processes. In order to accomplish the demand-oriented configuration of the application at all times, CeramOptec is available to assist customers through extensive guidance and test-runs within their own production process.

The SmartsplicerTM was developed as the result of a research project, in which aside from Nyfors and CeramOptec, also the Fraunhofer-Institut für Angewandte Optik und Feinmechanik (IOF) [Fraunhofer Institute for Applied Optics and Precision Engineering] in Jena participated. While Nyfors developed the laser system and Fraunhofer IOF the optical components, CeramOptec was in charge of consistently testing the individual application scenarios. Additional information about CeramOptec“s fusion splicing portfolio, as well as the guidance and test offer, are available online at www.ceramoptec.com

About CeramOptec
CeramOptec specialises in the production of multimode optical fibres made of quartz glass. Founded in 1988, today this medium-sized company is a subsidiary of biolitec AG, one of the world’s leading medical technology companies in the field of laser applications. With offices in China and distribution partners in the USA, India, Japan and Korea, CeramOptec is strongly represented not only in Europe, but also in the Asian and North American markets. The company“s product portfolio includes fibers, fiber bundles, assemblies and cables for a wide range of applications, including industrial and medical laser applications, aerospace sensor systems and spectroscopic applications in astronomy and the chemical industry. A special feature is the manufacture of glass fiber cores with rectangular through to octagonal geometry (Non Circular Core Fibres/NCC), which are used especially in astrophysics. The biolitec group employs a total of 245 people.

Company-Contact
CeramOptec GmbH
Holger Bäuerle
Brühler Straße 30
53119 Bonn
Phone: +49 (0) 228 / 97 967-12
Fax: +49 (0) 228 / 97 967-99
E-Mail: holger.baeuerle@ceramoptec.com
Url: http://www.ceramoptec.com

Press
fr financial relations gmbh
Jörn Gleisner
Louisenstraße 97
61348 Bad Homburg
Phone: +49 61 72 / 27 15 9 – 20
E-Mail: j.gleisner@financial-relations.de
Url: http://www.financial-relations.de/cms/front_content.php

Science Research Technology

Experts on hand to answer patients‘ questions

First retinitis pigmentosa patient day organised by university eye hospital is a great success

Experts on hand to answer patients

Retinitis pigmentosa patient day: Prof. E. Zrenner, PD Dr. K. Stingl, P. Böhm (from right) (Source: Retina Implant AG/Bernhard Krause)

(Reutlingen/Tübingen) – The first retinitis pigmentosa patient day at the ophthalmology department of the University Eye Hospital in Tübingen was a great success. Last Saturday, under the banner „Meet the Experts“, world-renowned specialists offered blind and visually impaired people and their families an overview of the latest research. Patients being treated using transcorneal electrical stimulation or who have received an electronic retinal implant gave first-hand accounts of their experiences.

„Tomorrow sees the start of the „Week of Sight“,“ said Prof. Eberhart Zrenner, welcoming visitors to the first retinitis pigmentosa patient day in Tübingen last Saturday. This exceptional event, hosted by the Centre for Rare Diseases (ZSE) at the University Eye Hospital’s ophthalmology department, fitted perfectly into the Germany-wide campaign that brings together activities under the key theme of „Understanding and preventing blindness“ from 8 to 15 October 2017. Over 500 participants, visually impaired people and their families came along to Tübingen. Due to the high level of interest, the proceedings had to be moved to a much larger auditorium near the new University Eye Hospital in Tübingen before the event got under way.

The slogan of the patient day – „Meet the Experts“ – more than lived up to its name. Prof. Zrenner, Dr. Katarina Stingl, Prof. Karl Ulrich Bartz-Schmidt, Dr. Andreas Schatz and Prof. Dominik Fischer – internationally renowned specialists from medicine and research at the University Hospital of Tübingen – came together to answer participants‘ questions in person.

Dr. Stingl, who is responsible for surgery for congenital retinal diseases at the University Eye Hospital in Tübingen as Prof. Zrenner’s successor, won the 2017 Retinitis Pigmentosa Research Prize from the PRO RETINA Deutschland patient association just a few days prior to the event. Among other things, she spoke about the latest studies on retinal implants. Retinal implants can help some blind patients regain part of their sight. Prof. Fischer informed visitors about the possibilities offered by gene therapy, although these are still in the study phase. Prof. Bartz-Schmidt, the Medical Director of the University Eye Hospital in Tübingen and one of the world’s few specialists who can perform this operation, then explained how a subretinal optic chip is implanted. He also presented other visual protheses that have been implanted in Cologne. The audience listened attentively to the remarks by Prof. Zrenner, too. He described the state of research relating to treatment options for RP. He explained that, depending on the patient and the progression of the disease, a decision has to be made on whether prevention, retention or restoration is appropriate. Medication-based treatment, gene therapy, electrical stimulation or electronic implants could thus be possible. Dr. Schatz, whose roles include that of study manager in the Experimental Electrophysiology department at the eye hospital, used his presentation „Transcorneal electrical stimulation (TES) – an initial treatment option for RP“ to explain what conditions need to be met to decelerate the progression of retinitis pigmentosa in patients with sufficient residual vision using electrical simulation.

Alongside the presentations by the experts, what made the patient day so extraordinary for patients were the reports by other affected people such as Verena Heier. The 26-year-old RP patient travelled from Cologne to talk about her personal experiences with electrical stimulation: „TES treatment gives me the reassurance of doing something to combat the progression of the disease.“ Having the feeling of being able to do something to fight the disease was also important to Peter Böhm when he had the implant inserted at the age of 47. Böhm, an IT consultant, outlined his experiences with the chip: „The chip helped me to better find my way around in the dark, especially with strong light sources and contrasts. However, this isn’t possible without training.“ Miikka Terho from Finland was introduced by Prof. Zrenner as a true pioneer, because in 2008 he was one of the first patients in the world to be implanted with the chip from Retina Implant. Terho was not only able to read his name, which was laid-out in front of him in 8 cm white letters on a black background, but was even able to correct it: „A man who had until now been blind points out a spelling mistake in his name,“ said Prof. Zrenner, describing the research success, which caused quite a stir at the time. Following successful reimplantation, the completely blind RP patient now wears the enhanced version of the chip – the RETINA IMPLANT Alpha AMS, which has CE certification.

Karin Papp, a representative of self-help organisation PRO RETINA Deutschland e.V., gave a very moving description of how, despite all the advances in medicine, a retinitis pigmentosa diagnosis is still initially a shock. She herself suffers from the condition and described how it feels when a doctor explains to a patient that he or she is suffering from an incurable disease that will lead to destruction of the retina and usually total blindness in the final stage. An unwillingness to accept the apparently inevitable progression of this hereditary degenerative retinal condition certainly acted as an impetus for many of the assembled participants. And even though the experts could not – and would not – promise them any miracles, they were nevertheless able to convey a powerful message that there has never been so much promising research into understanding and preventing blindness.

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: https://www.retina-implant.de/en/

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

perma STAR VARIO Gen. 2.0

One lubrication system for all types of applications

perma STAR VARIO Gen. 2.0

perma STAR VARIO installed on an electric motor

Euerdorf, Germany – Lubrication plays an important role in maintenance programs. Equipment breakdowns caused by insufficient or incorrect lubrication can have fatal and costly consequences. In some cases they can even stop the entire production. Correct lubrication is therefore a basic requirement for trouble-free operation. The new perma STAR VARIO ensures optimum lubrication regardless of changing temperatures, high counter pressure, or contamination at the lubrication point.

The electromechanical lubrication system was invented 15 years ago and has proven itself in all kinds of industries. The new version offers many improvements: LCD-display with push button control, all around LED lights and a new design.

The LCD-display with push button control is self-explanatory and makes programming extremely simple. The all around LED signal offers visual control of the operating status even from a distance. The system assembles and installs in just minutes. With a pressure build-up of up to 6 bar it works reliably over a wide temperature range from -10 °C to +60 °C.

Fast, easy set up

perma STAR VARIO consists of a transparent LC unit filled with oil or grease, a powerful battery set, and a reusable drive unit. Just insert the battery, screw drive unit and LC unit together, push the button to enter the desired discharge period (1 – 12 months) and LC size (60, 120, 250 cm³) and the system is ready to go.

One lubrication system for all types of applications

perma STAR VARIO is suitable for indoor or outdoor applications with high or low ambient temperatures. The high pressure build-up to 6 bar makes it possible to install perma STAR VARIO at remote locations, away from dangerous areas, with extension tubes up to a length of 5 meters. Not only does this save time when the lubrication system is exchanged, but it also tremendously reduces the risk of workplace accidents. With its three different sizes and many possible settings, perma STAR VARIO is a preferred system for electric motors with very specific relubrication amounts. The all around LED signal light lets you monitor the operational status from a distance. The new design protects the drive unit from water and makes the system better suited for applications in moist and wet surroundings.

Environmentally friendly lubrication

perma STAR VARIO can be individually programmed to exactly meet the lubrication requirements of different applications. The system continuously discharges small lubricant amounts at specified intervals. This lowers lubricant consumption and prevents over-lubrication and lubricant spills. The reusable drive unit reduces maintenance costs and saves valuable resources. We are taking service a step further.

Our extensive perma accessory range includes connecting parts for just about all applications like electric motors, conveyor systems, pumps, fans and blowers. To make your start into perma automatic lubrication easier, we have developed special mounting sets. Our perma SELECT software helps you find the ideal lubrication system and the most suitable lubricant for your application. You can download it free of charge. Our team of lubrication experts will be glad to answer any questions, assist you with challenging applications, or visit you on site.

Technical data

Drive – reusable: Electromechanical
Power supply: TAR VARIO battery set 4.5 V
Discharge period: 1, 2, 3, … 12 months
Lubricant volume: 60 cm³, 120 cm³ or 250 cm³
Operating temperature: -10 °C to +60 °C
Pressure build-up: 6 bar
Protection class: IP 65
Lubricants: Oil / grease up to NLGI 2
Certifications: UL

perma-tec has been providing innovative and creative lubrication solutions for more than 50 years. Our single- and multi-point lubrication systems can be found in almost all types of industries and applications around the world.

perma-tec´s leadership in single-point lubrication is based on many patents and certifications. All perma products are developed, tested and manufactured in the company´s German headquarters and live up to the „Made in Germany“ quality.

With many years of experience and a network of subsidiaries and competent partners around the world we can offer our customers lubrication solutions that meet highest technical requirements.

Contact
perma-tec GmbH & Co. KG
Doris Bauer
Hammelburger Straße 21
97717 Euerdorf
Phone: +49 9704 609-3663
E-Mail: d.bauer@perma-tec.de
Url: http://www.perma-tec.com

Science Research Technology

BHS-Sonthofen: Mixers from Bavaria on the roof of the world

Mixing hydro dram concrete: Twin-shaft batch mixers deployed 3,700 m above sea level

BHS-Sonthofen: Mixers from Bavaria on the roof of the world

The six BHS-Sonthofen mixers are located in the building holding the batcher that feeds aggregates

Six twin-shaft batch mixers of type DKX 6.0 delivered by BHS-Sonthofen are producing the concrete needed to build the main embankment of the Dagu hydro dam undergoing construction near the Tibetan city of Zangmu. The construction site is located 3,700 m above sea level, making this the most elevated site ever for employing mixers from BHS. BHS-Sonthofen specially modified the mixers to meet the challenges they are facing at this extreme altitude.

The first two mixers of type DKX 6.0 started producing the first batches of concrete on 12 July 2017. Two months later, Sinohydro No. 9 Engineering Company commissioned four more units. The mixers will produce approximately three million tons of roller compacted concrete (RCC) over the course of the dam“s construction, which is scheduled for completion in 2019. The complete facility, which comprises six mixers, is dimensioned to produce 160,000 m³ of hardened concrete per month.

The mixers are equipped with a coarse-grain mixing unit for processing grain sizes up to 160 mm, as is typical in hydro dam construction. This mixer type has proven its worth in numerous installations across the globe.

About 6 m³ of hardened concrete are discharged per batch at a rate of up to 48 cycles per hour, resulting in a total yield of up to 288 m³ of hardened concrete in one hour. The cycle times are short due to the intensive mixing of the concrete and the extra-large rotary valves at the underside of the mixing trough, which significantly speed up the discharge process.

Given the vast amount of concrete that needs to be processed, BHS-Sonthofen reinforced the mixing troughs with a tougher version of its 28-mm „Optilong“ wear tiles. The service life of these tiles is nearly twice as long as the diamond-shaped tiles commonly used in construction projects. The variable hardness of the individual tile rows ensures uniform abrasion across all wear zones.

BHS-Sonthofen even accounted for the remote location of the construction site: In order to prepare the machines for a potentially unstable grid, the company used special motor couplings. The hydrodynamic turbo couplings reduce mechanical as well as electrical load peaks. Thanks to this property, they have proven ideal for use in locations with critical grid fluctuations.

Also, since high-altitude air does not extract as much heat from the electric motors, BHS-Sonthofen equipped the mixers with special motors that feature type „H“ insulation.

The sheer remoteness of the construction site posed yet another challenge. The construction site in Tibet is nearly 4,000 km from Tianjin near Beijing, which is where BHS-Sonthofen“s Chinese subsidiary is situated. It took 20 days to transport the mixers across this distance.

The project:

Once completed, the Dagu dam will be 126 m tall with a dam crest measuring 385 m. The power plant will generate 640 MW of hydro energy.

The dam is part of a major project undertaken by the Chinese government to provide the eastern parts of the Tibetan Autonomous Region with electricity, all the way to remote villages. Multiple hydro dams are damming up the Yarlung Tsangpo, the Earth“s highest river. It crosses Tibet from west to east and continues through India, where it is called Brahmaputra.

About BHS-Sonthofen GmbH

BHS-Sonthofen GmbH is an owner-operated group of companies in the field of machinery and plant engineering based in Sonthofen, Germany. The company offers technical solutions for mechanical process technology, concentrating primarily on mixing, crushing, recycling and filtration. BHS-Sonthofen has a global presence, with more than 350 employees and several subsidiaries.

The Mixing Technology division produces batch and continuous mixers and offers the full range of process technology services for mixing applications. The twin-shaft batch mixer, which is considered a global benchmark in the concrete industry, is a key product.

Building companies use the mixers first and foremost to produce transport, precast, high-performance and hydro dam concrete or concrete paving blocks. BHS mixers are also highly suited for mixing dry mortar, cement and sand-lime products or for processing clay-and-rock mixtures.

They are widely used for processing mineral mixes, landfill substances, fly ash, dusts or other bulk materials, or for the conditioning of sludges and the production of suspensions. The latter is often done in the context of backfilling mines or depositing mineral waste.

For further information, please visit: www.bhs-sonthofen.de

Company-Contact
BHS-Sonthofen GmbH
Roland Schmid
An der Eisenschmelze 47
D-87527 Sonthofen, Germany
Phone: +49 8321 6099-231
E-Mail: press@bhs-sonthofen.de
Url: http://www.bhs-sonthofen.de

Press
VIP Kommunikation
Regina Reinhardt
Dennewartstr. 25-27
52068 Aachen, Germany
Phone: +49.241.89468-24
Fax: +49.241.89468-44
E-Mail: reinhardt@vip-kommunikation.de
Url: http://www.vip-kommunikation.de

Science Research Technology

Emissions analysis for the highest demands

The increasing sense of environmental awareness around the globe is demanding higher standards for environmental monitoring.

Emissions analysis for the highest demands

NOx electrodeless discharge lamp

Heraeus Noblelight has developed an easy to use, plug & play light solution based on NOx light technology, for very accurate measurement of NOx and other pollution gases.

Environmental monitoring is used to describe the various processes, tests and investigations that are carried out in order to monitor the state of the environment and its changes, to understand and protect it. One of the major monitoring areas is air quality monitoring, which requires highly accurate measuring instruments. Heraeus Noblelight“s new light solution is developed for high accuracy, fast and real-time NOx measurement, together with very low operating costs.

The Heraeus plug & play light solution
NOx instrument development based on UV Resonance Absorption Spectroscopy (UV-RAS) has been difficult in the past, due to challenges in tuning the UV-lamp operation within its environment to optimize lifetime and intensity.

The NOx electrodeless discharge lamp (EDL) is a lamp with N2, O2 gas fill that emits a spectrum in the wavelength range between 200 nm to 600 nm. NOx-specific spectral lines in the 200 nm region can be used for the detection of NO and NO2, H2S, NH3, SO2 and other pollution gases.
Heraeus Noblelight“s new plug & play light solution for reliable NOx measurement is a lamp module that offers a pre-tuned UV-light source in a stable environment to ensure optimized performance. The NOx lamp module has an integrated EDL and comes with the corresponding power supply combined in a box. This makes integration into an OEM UV-RAS system very easy and cost efficient, plus light source replacement at End Of Life is by simply replacing the module in the field.

Fast and very accurate
High accuracy and stability are required in any measurement process. The new NOx module delivers both and even more. It is easy and effective in use, and without the need for consumables, it ensures very low operating costs. Enabling fast and accurate absorption measurements without cross-interference from water and CO2 , it saves time during the measurement process and makes dynamic (real time) measurements possible with high measurement confidence – a real competitive advantage for UV-RAS compared to other technologies.

Different methods to measure NOx
NOx is a generic term for the nitrogen oxides NO and NO2. It reacts in our atmosphere to form a wide variety of toxic products, as well as supporting the formation of ground-level (tropospheric) ozone.
Sources of NOx are predominantly man-made: burning fossil fuels for energy generation, such as coal-,oil- and gas-fired power stations, refuse incineration, some chemical processes and vehicle fuels, like modern diesel cars, used for land, water and air transportation.

Common methods for measuring NOx include sensor technologies based on chemiluminescence and electrochemical techniques.
This requires conversion of NO2 to NO for measurement or calculation of the NO2 content based on an assumed NO:NO2 ratio. In addition, NOx can be measured with infrared radiation, which can be affected by the content of H2O and CO2 in the sample. Direct UV absorption measurement of both NO and NO2 is the more precise way to measure total NOx for continuous emissions monitoring, and measurement in the UV-region avoids the influence of H2O and CO2.

Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned company formed in 1851. With expertise, a focus on innovations, operational excellence and an entrepreneurial leadership, we strive to continuously improve the businesses of our customers around the world.
We create high-quality solutions for our customers and strengthen their long-term competitiveness by combining material expertise with technological know-how. Our ideas are focused on important issues such as the environment, energy, health, mobility and industrial applications. Our portfolio ranges from components to coordinated material systems which are used in a wide variety of industries, including the steel, electronics, chemical, automotive and telecommunications industries.
In the 2016 financial year, Heraeus generated revenues without precious metals of EUR2.0 bn and a total revenue of EUR21.5 bn. With approximately 12,400 employees worldwide in more than 100 subsidiaries in 38 countries, Heraeus holds a leading position in its global markets.
In 2016, the Foundation for Family Businesses named Heraeus as one of the „Top 10 Family Businesses“ in Germany.
Heraeus Noblelight GmbH with its headquarters in Hanau and with subsidiaries in the USA, Great Britain, France and China is one of the technology- and market-leaders in the production of specialty light sources and systems. In 2016, Heraeus Noblelight employed 707 people worldwide. The organization develops, manufactures and markets infrared and ultraviolet emitters, systems and solutions for applications in industrial manufacture, environmental protection, medicine and cosmetics, research, development and analytical measurement techniques.

Contact
Heraeus Noblelight GmbH
Juliane Henze
Heraeusstraße 12-14
63450 Hanau
Phone: +49 (6181) 35-8539
E-Mail: juliane.henze@heraeus.com
Url: https://www.heraeus.com/en/hng/products_and_solutions/lamps_for_optics_and_analytics/nox_measurement.aspx

Science Research Technology

„A bridge between patients, medicine and research“

Retina Implant at DOG 2017 – PRO RETINA´s „International Retina Day“

"A bridge between patients, medicine and research"

(Source: Retina Implant AG)

(Reutlingen/Berlin) – Retina Implant AG showcased its product developments as part of the 115th DOG Conference of the German Society of Ophthalmology, which was held in Berlin from 28 September to 1 October 2017. The medtech company also collaborated with PRO RETINA Deutschland e.V. to mark the „International Retina Day“ at the annual conference on September 30. Self-help organisation PRO RETINA offered visually impaired people the chance to join its patient register for free on this day. The patient register is hugely important for research and treatment of rare congenital retinal conditions such as retinitis pigmentosa.

For 15 years, Retina Implant AG has been working intensively on researching and treating rare congenital retinal conditions. The medtech company was therefore keen to support the initiative of PRO RETINA Deutschland e.V, a self-help organisation by and for people with retinal degeneration, which opened its patient register free of charge to people affected by these conditions for one day only on 30 September, „International Retina Day“. „The patient register is neutral, independent and, of course, anonymous. It enables people with specific kinds of visual impairment to help develop studies, because researchers who are working on a study can contact PRO RETINA, and we will then contact the patients,“ explains Markus Georg, Managing Director of PRO RETINA Deutschland e.V. „This means we can actively support ophthalmology research, especially research into rare conditions such as retinitis pigmentosa. Our database forms a bridge between patients, medicine and research.“

The subretinal implant from Retina Implant AG can help visually impaired patients who perceive very little or no light as a result of various kinds of degenerative retinal diseases such as retinitis pigmentosa to regain a certain degree of useful sight. Most patients with an implanted chip can identify light sources, for example, which makes it easier for them to find their way around a room again. „Everyone with an interest in research and development in the field of degenerative retinal conditions will welcome this PRO RETINA campaign,“ explains Reinhard Rubow, CEO of Retina Implant AG. „The patient register is an important tool for bringing together patients, families, doctors and scientists with the aim of improving treatment for people with RP. This is our job, too, and that is why we welcome and support this initiative.“

On the day before the DOG Conference, PRO RETINA also organised a patient symposium on „Retinal degeneration – insights and outlooks“. This included a presentation by Prof. Florian Gekeler from the Eye Clinic at Katharinenhospital Stuttgart, in which he outlined various treatment options, from transcorneal electrical stimulation to retinal chips. The RETINA IMPLANT Alpha AMS subretinal chip was also the subject of a presentation at the DOG conference given by Dr. Katarina Stingl from the Tubingen Ophthalmology Research Institute. She presented the results of the latest study investigating the effectiveness of the retinal implant in 15 blind patients with congenital retinal degeneration (“ Efficacy of retina implant alpha AMS in 15 patients blind from inherited retinal degenerations„).

Contact form for the PRO RETINA Deutschland e.V. patient register:
http://www.pro-retina.de/forschungsfoerderung/patientenregister/formular

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: https://www.retina-implant.de/en/

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Artificial vision – successes and challenges

Retina Implant AG at „The Eye & The Chip“ research congress in Detroit, USA

Artificial vision - successes and challenges

(Source: Retina Implant AG)

(Reutlingen/Detroit) – Retina Implant AG was at „The Eye & The Chip – World Congress on Artificial Vision“ in Detroit, USA, to showcase research results relating to its subretinal implant. The annual congress is organised by the Detroit Institute of Ophthalmology, which is part of the Henry Ford Hospital. The event is a forum for interdisciplinary collaboration between specialists from across the world and focuses on advances in nanoelectronics and neurobiology that relate to „artificial vision“.

The subretinal implant from Retina Implant AG can help patients who perceive very little or no light as a result of the degenerative disease retinitis pigmentosa to regain a certain degree of useful sight. Most patients with an implanted chip can identify light sources, which makes it easier for them to find their way around a room again.

In his presentation at the congress, Dr. Alfred Stett, CTO of Retina Implant AG, described the design features of the subretinal implant to the assembled international specialists. The latest generation of the chip, the RETINA IMPLANT Alpha AMS, has virtually no externally visible electronic components. Only a small transponder that connects with the chip´s external power supply is embedded under the skin behind the ear. The chip is only around 12 square millimetres in size and is placed directly below the fovea centralis, which means it can move with the eye. This allows patients to use natural (previously learned) eye movement to locate objects.

Prof. Eberhart Zrenner, Senior Professor of Ophthalmology at the Werner Reichardt Centre for Integrative Neurosciences, which is part of the Institute for Ophthalmic Research at Eberhard Karls Universität Tübingen, presented the results of the latest clinical study ( „Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations„).

Dr. Günther Zeck from the Natural and Medical Sciences Institute (NMI) at the University of Tübingen gave a presentation entitled „Single-Pixel Stimulation of Blind Rodent Retina Using a Subretinal Implant“, in which he described how he uses the chip under laboratory conditions for his research into electrical stimulation of the retina.

The presentations, which covered the full spectrum from basic research and technology to clinical studies was debated intensively by the scientific community. „This congress brings together all the working groups around the world that are studying ´artificial vision using implants´,“ explained Dr. Stett. „Scientists, doctors, engineers and manufacturers report on their achievements – and the challenges that still need to be overcome.“ A great emphasis was placed on two key elements – firstly, the need for uniform test methods for measuring the quality of vision and, secondly, ensuring the effectiveness of the various treatment approaches can be compared. The congress delegates also agreed on the importance of applying strict selection criteria when determining which patients are suitable candidates for an implant and on the high value of intensive training after implantation.

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: http://implant.de

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

PRO RETINA patient association recognises research into sub-retinal electronic implants

Retina Implant AG: Dr. Katarina Stingl wins Retinitis Pigmentosa Research Prize 2017

PRO RETINA patient association recognises research into sub-retinal electronic implants

Dr. Katarina Stingl (Source: Dr. Katarina Stingl)

(Reutlingen/Berlin) – This year´s Retinitis Pigmentosa Research Prize for preventing blindness, which is jointly awarded by the PRO RETINA Deutschland patient associations and Retina Suisse, was given to Dr. Katarina Stingl. The consultant ophthalmologist received the award during the 115th Congress of the German Society of Ophthalmology (DOG) in Berlin in recognition of two studies relating to sub-retinal electronic implants in patients with retinitis pigmentosa.

Prof. Eberhart Zrenner, Chairman of the Scientific and Medical Advisory Board of PRO RETINA Deutschland e.V., a self-help group by and for people with retinal degeneration, delivered the laudation and stressed that Dr. Stingl´s work makes her one of the most promising young scientists in the field of clinical experimental research into degenerative retinal conditions and their treatment. Dr. Stingl qualified as a university lecturer at Eberhard Karls University of Tübingen, in 2015, and has been working as a consultant for congenital retinal conditions in the ophthalmology department there since 2016.

Retina Implant AG feels that the scientific work of Dr. Stingl is of vital importance. We would like to congratulate her on this award, and thank her for her valuable scientific contribution,“ explains Reinhard Rubow, CEO of Retina Implant AG. „The Retinitis Pigmentosa Research Prize 2017 also motivates our employees to continue their intensive efforts in researching and treating rare congenital retinal conditions. PRO RETINA´s impetus and initiatives help shape the interaction between hospitals, patients and doctors – and that includes this prize. The PRO RETINA patient register was also launched at the DOG. This is hugely important for clinical research, and we hope that as many patients as possible will join the register so that future research such as that of Dr. Stingl will be of increasing benefit for all RP patients.“

Contact form for the PRO RETINA Deutschland e.V. patient register:
http://www.pro-retina.de/forschungsfoerderung/patientenregister/formular

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: http://implant.de

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Reimbursement of retinal implant for a limited number of patients

French health authority HAS approves Forfait Innovation application by Retina Implant AG

Reimbursement of retinal implant for a limited number of patients

(Source: Retina Implant AG)

(Reutlingen, Germany/Saint-Denis, France) – French health authority HAS (Haute Autorite de Sante) has just approved the Forfait Innovation application by Retina Implant AG to assess the benefits of its RETINA IMPLANT Alpha AMS subretinal implant. The procedure evaluates innovative technologies in the healthcare sector to quickly make them available to patients. As part of the Forfait Innovation process, over a two-year period the costs will be covered for the implant and treatment of a limited number of patients who perceive little or no light. Retina Implant AG fund the costs for the accompanying study, which is examining the impact of the implant on participants` daily lives (Impact on daily life of patients using the subretinal implant RETINA IMPLANT Alpha AMS).

Following the successful conclusion of the study, the implant will be added to the list of approved services of health insurance companies in France. As a result of the reimbursement, an innovative technology can be made available to patients with the hereditary retinal disease retinitis pigmentosa (RP), which leads to total blindness in the final stage. Although RP is a rare disease, some 130,000 people suffer from it in Europe alone. The subretinal implant is virtually invisible except for a small transponder fixed behind the ear. The implant can partially restore the sight of blind people suffering from RP. This means a large proportion of patients can make out light sources with the RETINA IMPLANT Alpha AMS and thus find their way around a room, for example.

„For some time now, work has been in progress to focus attention on the practical benefits for visually impaired people in their everyday lives, alongside standard sight measurements. We`re delighted this study is taking particular account of this aspect,“ explains Jürgen Klein, Sales and Marketing Director at Retina Implant AG. „France is therefore taking a leading role in Europe in evaluating subretinal implants.“ The study will be performed in close cooperation between the university hospital CHU Montpellier for screening and patient follow-up and the implantation centre Clinique St Jean in Montpellier for the surgery, with further centres planned.

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: http://implant.de

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de